Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has extended the approval of Praluent as an adjunct to diet and other low-density lipoprotein cholesterol lowering therapies to include pediatric patients aged 8 and older with heterozygous familial hypercholest
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1116617012-6a8112931e6f4375b6e1481b39eeeae8.jpg "How to Become a Real Estate Agent: A Step-by-Step Guide")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1255077848-13fe034d27ba4d1398930d76d7be6693.jpg "6 Best Paying Jobs in Finance")